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ABSTRACT
PKR is an interferon (IFN)-induced protein kinase,
which is involved in regulation of antiviral innate
immunity, stress signaling, cell proliferation and
programmed cell death. Although a low amount of
PKR is expressed ubiquitously in all cell types in the
absence of IFNs, PKR expression is induced at
transcriptional level by IFN. PKR’s enzymatic activity
is activated by its binding to one of its activators.
Double-stranded (ds) RNA, protein activator PACT
and heparin are the three known activators of PKR.
Activation of PKR in cells leads to a general block in
protein synthesis due to phosphorylation of eIF2a on
serine 51 by PKR. PKR activation is regulated very
tightly in mammalian cells and a prolonged activa-
tion of PKR leads to apoptosis. Thus, positive and
negative regulation of PKR activation is important
for cell viability and function. The studies presented
here describe human dihydrouridine synthase-2
(hDUS2) as a novel regulator of PKR. We originally
identified hDUS2 as a protein interacting with PACT
in a yeast two-hybrid screen. Further characteriza-
tion revealed that hDUS2 also interacts with PKR
through its dsRNA binding/dimerization domain and
inhibits its kinase activity. Our results suggest that
hDUS2 may act as a novel inhibitor of PKR in cells.
INTRODUCTION
Interferons (IFNs) are cytokines with antiviral, antipro-
liferative and immunomodulatory properties, which they
exert by inducing synthesis of several proteins (1,2). The
IFN-induced, dsRNA-activated protein kinase PKR, a
serine/threonine kinase, is a major mediator of the
antiproliferative and antiviral actions of IFN (3–6).
Although induced at the transcriptional level by IFNs,
PKR is present at a low, basal level in most cell types (7).
PKR’s kinase activity stays latent until it binds to one of
its three known activators, double-stranded (ds) RNA,
heparin and the protein activator PACT. In virally
infected cells, dsRNA produced during viral replication
or viral RNAs with extensive ds regions serve as PKR
activators (8,9). Polyanionic agents such as heparin
also activate PKR both in vitro (10) and in vivo (11). In
addition, PACT is a cellular, protein activator of PKR,
which heterodimerizes with PKR and activates it in the
absence of dsRNA (12,13), thereby playing an important
role in PKR activation in response to stress signals (14).
The a-subunit of the eukaryotic protein synthesis initia-
tion factor eIF-2 (eIF2a) is the most studied physiological
substrate of PKR. Phosphorylation of eIF2a on Ser51 by
PKR leads to an inhibition of protein synthesis (15,16).
In addition to its central role in antiviral activity of IFNs,
PKR is also involved in the regulation of apoptosis
(17,18), cell proliferation (4,5), signal transduction (19–21)
and diﬀerentiation (22,23).
The dsRNA-mediated activation of PKR has been
characterized in detail (24–29). The dsRNA-binding
domain (dsRBD) of PKR is composed of two copies of
the dsRNA-binding motif (dsRBM), a sequence motif
conserved in many RNA-binding proteins (30,31).
Binding of dsRNA to PKR through these motifs causes
a conformational change (32,33) that leads to an
unmasking of the ATP-binding site in the kinase domain
and results in autophosphorylation of PKR on several
sites (34–36). The domains that are involved in dsRNA
binding are also involved in mediating dimerization of
PKR, which is essential for its kinase activity in the
presence of dsRNA (37–40). Although the same domain
mediates PKR’s dsRNA binding and dimerization,
distinct residues have been identiﬁed that contribute to
one or both of these properties (40). Heparin binds to
PKR at a site that is nonoverlapping with PKR’s dsRBD
and leads to PKR activation (41,42). Activation of PKR
by heparin in vascular smooth muscle cells leads to an
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p27
kip1 protein levels, inhibition of Cdk2 activity and Rb
phosphorylation (43). PACT interacts with PKR by
binding to its dsRBD in a dsRNA-independent manner
and activates PKR in response to cellular stress (14).
Stress signals lead to phosphorylation of PACT at serine
287, which causes its higher aﬃnity association with PKR
leading to PKR activation, eIF2a phosphorylation and
consequent inhibition of translation (44). PACT has three
copies of dsRNA binding/dimerization motifs and the two
amino-terminal copies are required for high-aﬃnity
binding to PKR (45). The third, carboxy-terminal motif
is required for PKR activation presumably by making a
direct contact with PKR’s catalytic domain (45,46).
Several cellular and viral inhibitors of PKR have been
identiﬁed (47). P58
IPK, the trans-activation response
(TAR) RNA-binding protein (TRBP), nucleophosmin
(NPM) and several virally encoded proteins inhibit
PKR activity. Since PKR activation leading to eIF2a
phosphorylation and inhibition of translation would be
detrimental to viral replication, various viruses have
developed eﬃcient mechanisms to inhibit PKR activation
(9,48,49). In this article, we report the identiﬁcation of
hDUS2 as a novel cellular PKR inhibitor. hDUS2 was
identiﬁed as a PKR- and PACT-interacting protein using
PACT as a bait protein in yeast two-hybrid screen. hDUS2
was reported recently to be the human homolog of
Saccharomyces cerevisiae dihydrouridine synthase 2
(Dus2) enzyme (50). It was also shown to possess tRNA-
dihydrouridine synthase (DUS) activity. hDUS2 has one
copy of the conserved dsRBM and our results indicate that
hDUS2 interacts with PKR and PACT via its dsRBM.
Binding of hDUS2 with PKR resulted in an inhibition of
PKR activity both in vitro as well as in mammalian cells.
Furthermore, hDUS2 overexpression inhibited stress-
induced apoptosis in HT1080 cells indicating that it acts
as an important negative regulator of PKR activity in cells.
MATERIALS AND METHODS
Yeast two-hybrid screening forPACT-interacting proteins
The PACT coding region expressed as a GAL DNA-
binding domain fusion protein was used as bait. A total of
3 million transformants from a human placenta match-
maker library (Clontech) were screened in the yeast strain
HF7c (Clontech) and 250 colonies were recovered
on triple dropout medium lacking histidine, leucine
and tryptophan, out of which 22 tested positive for
b-galactosidase. On further analysis, 18 of these were
dependent on PACT to give a positive b-galactosidase
reaction. These clones were subjected to a second screen to
ensure that they gave a positive b-galactosidase reaction in
a manner speciﬁc for co-expression of PACT. One of these
clones (hDUS2), which did not contain a full-length
cDNA insert, was analyzed further. Sequence analysis of
the cDNA clones revealed that they originated from three
unrelated genes. There were 14 clones isolated that coded
for the PACT protein and the other three encoded a
protein that has been characterized as a zinc ﬁnger protein
just another zinc-ﬁnger (JAZ) that interacts with PKR.
b-Galactosidase reporter assay inyeast
HF7c yeast reporter strain containing the LacZ-Gal4-
inducible gene were co-transformed with the indicated
plasmids and plated on selective medium lacking trypto-
phan and leucine. Double transformants were streaked on
selective medium, replica-lifted on nitrocellulose ﬁlters
and tested for b-galactosidase activity (51).
Cloning full-length hDUS2 openreading frame
The full-length open reading frame of hDUS2 was
ampliﬁed by RT–PCR using the sequence information
from Genbank and the appropriate primers. The
full-length open reading frame was then sub-cloned
into pGBKT7 and pGADT7 (Clontech) vectors, and
pCDNA3.1(–) (Invitrogen) vector. Cloning in pCDNA3.1
(–) vector was designed such that it would add a ﬂag tag at
the amino-terminus of hDUS2.
Invitro protein–protein interaction assay
In vitro translated,
35S-labeled hDUS2 protein was synthe-
sized using the TNT T7 coupled reticulocyte system from
Promega. Five microliters of the in vitro translated
35S-labeled proteins were incubated with 1mg of pure
recombinant PACT or PKR and 20ml of Ni-agarose
(Novagen) in 200ml of binding buﬀer [5mM imidazole,
20mM Tris–HCl pH 7.9, 200mM NaCl, 0.2mM phenyl-
methylsulfonyl ﬂuoride (PMSF), 0.5% IGEPAL (Sigma)]
at 258C for 30min on a rotating wheel. The beads were
washed four times in 500ml of binding buﬀer each time and
the washed beads were then boiled in 20ml Laemmli buﬀer
(150mM Tris–HCl pH 6.8, 5% SDS, 5% b-mercap-
toethanol, 20% glycerol) for 2min and eluted proteins
were analyzed by SDS–PAGE on a 12% gel. Fluorography
was performed at  808C with intensifying screens.
dsRNAbinding assay
The in vitro translated,
35S-labeled PKR, PACT and
hDUS2 proteins were synthesized using the TNT T7
coupled reticulocyte lysate system from Promega.
The dsRNA-binding activity was measured by poly(I)–
poly(C)–agarose binding assay. The translation products
(4ml) diluted with 25ml of binding buﬀer [20mM Tris–
HCl, pH 7.5, 0.3M NaCl (or 50mM NaCl), 5mM MgCl2,
1mM DTT, 0.1mM PMSF, 0.5% NP-40, 10% glycerol)
were mixed with 25ml of poly(I)–poly(C)–agarose
(Pharmacia) beads and incubated at 308C for 30min
with intermittent shaking. The beads were then washed
four times with 500ml of binding buﬀer each time. The
proteins bound to beads after washing were analyzed by
SDS–PAGE followed by ﬂuorography.
Expression in mammalian cells and
co-immunoprecipitation assay
HeLa cells were co-transfected in 100mm culture
dishes with 5mg each of (i) negative control: HA-B56a/
pCDNA3.1(–) and ﬂag-hDUS2/pCDNA3.1(–), (ii)
HA-PKR/pCDNA3.1(–) and ﬂag-hDUS2/pCDNA3.1(–)
or (iii) HA-PACT/pCDNA3.1(–) and ﬂag-hDUS2/
pCDNA3.1(–) using the Eﬀectene (Qiagen) reagent.
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Cells were washed in ice-cold PBS and collected by
centrifugation at 600g for 5min. They were lyzed by
addition of an equal volume of lysis buﬀer (20mM Tris–
HCl pH 7.5, 100mM NaCl, 1mM EDTA, 1mM
dithiothreitol, 100U/ml aprotinin, 0.2mM phenylmetha-
nesulfonyl ﬂuoride, 20% glycerol, 1% Triton X-100).
The lysates were centrifuged at 10000g for 5min and
the supernatants were collected as total cell extract.
One hundred micrograms of total protein was used
to immunoprecipitate ﬂag-hDUS2 with anti-ﬂag mAb–
agarose in immunoprecipitation buﬀer (20mM Tris–HCl
pH 7.5, 100mM NaCl, 1mM EDTA, 1mM dithiothreitol,
100U/ml aprotinin, 0.2mM phenylmethanesulfonyl ﬂuor-
ide, 20% glycerol, 1% Triton X-100). The agarose beads
were washed four times with 500ml of IP buﬀer each time.
The proteins bound to the beads were then analyzed by a
western blot analysis with the anti-HA tag and anti-ﬂag
tag monoclonal antibodies (Sigma).
PKR kinase activity assay
PKR activity assays were performed using an anti-PKR
monoclonal antibody (R & D systems; 71/10). HeLa M
cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium containing 10% (v/v) fetal calf serum. The cells
were harvested when they were at 70% conﬂuency. Cells
were washed in ice-cold PBS and collected by centrifuga-
tion at 600g for 5min. They were lyzed by addition of an
equal volume of lysis buﬀer (20mM Tris–HCl, pH 7.5,
5mM MgCl2, 50mM KCl, 400mM NaCl, 2mM DTT,
1% Triton X-100, 100U/ml aprotinin, 0.2mM PMSF,
20% glycerol). The lysates were centrifuged at 10000g for
5min and the supernatants were assayed for PKR activity.
A 100mg aliquot of total protein was immunoprecipitated
using anti-PKR monoclonal antibody (71/10) in high-salt
buﬀer (20mMTris–HCl, pH 7.5, 50mM KCl, 400mM
NaCl, 1mM EDTA, 1mM DTT, 100U/ml aprotinin,
0.2mM PMSF, 20% glycerol, 1% Triton X-100) at 48C
for 30min on a rotating wheel. Then 10ml of Protein
A-Sepharose slurry was added and incubation was carried
out for a further 1h. The Protein A-Sepharose beads were
washed four times in 500ml of high-salt buﬀer and twice in
activity buﬀer (20mM Tris–HCl, pH 7.5, 50mM KCl,
2mM MgCl2, 2mM MnCl2, 100U/ml aprotinin, 0.1mM
PMSF, 5% glycerol). The PKR assay was performed with
PKR still attached to the beads in activity buﬀer contain-
ing 0.1mM ATP and 1mCi of [g
32P] ATP at 308C for
10min. The standard activator of the enzyme was 0.1mg/
ml poly(I)-poly(C) or 0.116pmol of pure PACT protein.
Puriﬁed hDUS2 protein in varying amounts as indicated
was added to test its eﬀect on PKR activity. Labeled
proteins were analyzed by SDS–PAGE on a 12% gel
followed by autoradiography.
Translationinhibition assay
The eﬀect of co-transfection of pCDNA3.1(–) empty
vector, TRBP/pCDNA3.1(–) and hDUS2/pCDNA3.1(–)
on the reporter pGL2-Control (Promega) in HeLa cells
was measured as described before (52). HeLa cells were
transfected in six-well plates in triplicate with the indicated
plasmids using Eﬀectene transfection reagent. At 24h
after transfection, the cells were treated with 100U/ml of
IFN-b. Cells were harvested 48h after transfection and
assayed for luciferase activity after normalizing for the
transfection eﬃciency by measuring the total protein.
Apoptosis assay
HT1080 cells were grown to 50% conﬂuency on coverslips
in six-well plates and co-transfected with 500ng of the
indicated eﬀector and 100ng of pEGFPC1 (Clontech)
plasmid using the Eﬀectene reagent. The cells were
observed for green ﬂuorescent protein (GFP) ﬂuorescence
24h after transfection using an inverted ﬂuorescence
microscope, and were then treated with 0.1mg/ml tunica-
mycin to induce ER stress and apoptosis. At 24 and 48h
after this treatment, the cells (coverslips) were washed
twice with PBS and ﬁxed in acetone:methanol (1:1, v/v)
for 1min, and were mounted in Vectashield (Vector
Laboratories) mounting medium containing DAPI
(4,6-diamidino-2-phenylindole). At least 300 ﬂuorescent
(GFP-positive) cells were counted as alive or dead, based
on their morphology and nuclear DAPI staining. Intense
DAPI staining indicates nuclear condensation, which is a
hallmark of apoptosis. The experiment was repeated three
times and the counting was done in a blinded manner to
ascertain the validity of obtained numbers. The cells
showing a normal ﬂat morphology were scored as alive,
and cells showing cell shrinkage, membrane blebbing,
rounded morphology, partial detachment from the plate
and chromatin condensation (intense DAPI stain) were
counted as dead. Apoptosis (%)=(ﬂuorescent cells with
intense DAPI staining in the nucleus/total ﬂuorescent
cells) 100.
RESULTS
hDus2 interacts withboth PACT andPKR
Various stress signals induce cellular apoptosis via
activation of PKR (18). PACT plays a central role in
this pathway by functioning as an activator of PKR
(13,14). In order to identify proteins that may regulate this
stress-activated apoptotic pathway, we performed a yeast
two-hybrid screen using PACT as a bait. Among the
cDNA clones identiﬁed as the ones that encoded PACT-
interacting proteins, there were 14 isolates of PACT, 3
isolates of JAZ and 1 isolate of hDUS2 (human
dihydrouridine synthase-2). PACT is expected to interact
with itself to form dimers/multimers since it has three
copies of dsRBM, a conserved protein motif involved in
dsRNA binding as well as dimerization (45,46). JAZ has
been previously shown to interact with dsRNA (53).
hDUS2 encodes for a human tRNA modiﬁcation enzyme,
dihydrouridine synthase (50). Four dihydrouridine
synthases have been identiﬁed in human cells and these
show homology with the yeast enzymes that have been
characterized before. hDUS2 has never before been
described to interact with PKR or PACT and thus we
characterized this interaction further. The original hDUS2
cDNA insert isolated from the yeast two-hybrid library
was a partial cDNA clone and lacked the amino-terminal
1000 Nucleic Acids Research, 2008, Vol. 36, No. 3sequences that encoded the amino-terminal 320 amino
acids. We obtained the full-length cDNA clone for
hDUS2 based on the Genbank sequence information
(FLJ20399, accession no. NM_017803) by performing
RT–PCR on total RNA isolated from HeLa cells. The
full-length open reading frame for hDUS2 was sub-cloned
into the yeast two hybrid vectors pGBKT7 and pGADT7
to obtain GAL4 DNA-binding domain fusion and GAL4
activation domain fusion, respectively. In order to conﬁrm
that the full-length hDUS2 protein can interact with
PACT and to test if hDUS2 interacts with PKR we
performed the yeast growth assay on triple drop-out
medium lacking three amino acids: histidine, leucine and
tryptophan. Growth on the triple drop-out medium
indicates positive interaction between the two proteins
that are being tested. As seen in Figure 1A, hDUS2
showed positive interaction in both combinations with
PKR (sectors B and E), as well as PACT (sectors C and
F). The negative controls with empty vectors did not show
any growth on the plate (sectors A and D). These results
conﬁrmed that full-length hDUS2 interacts with both
PACT and PKR. In order to further conﬁrm the positive
interaction between hDUS2, PKR and PACT we also
tested activation of another reporter, b-galactosidase.
Expression of b-galactosidase in yeast cells is indicated
by blue color and occurs only if the proteins encoded by
pGADT7 and pGBKT7 constructs interact. As seen in
Figure 1B, PKR/pGBKT7 and PACT/pGBKT7 both
showed a positive interaction with hDUS2/pGADT7. The
opposite combinations also showed blue color and thus
conﬁrmed the interactions. The negative controls with
p53/pGBKT7 and p53/pGADT7 all showed white color
indicating no interaction with hDUS2, PKR and PACT.
These results conﬁrm the speciﬁcity of the interaction
between hDUS2 and PKR or PACT. The interaction of
hDUS2 with PACT and PKR was further conﬁrmed by
performing a biochemical interaction assay. In vitro
translated,
35S-methionine labeled hDUS2 was allowed
to interact with pure, recombinant hexahistidine tagged
PKR or PACT proteins and was then pulled-down using
Ni-agarose beads. As seen in Figure 1C, hDUS2 showed
no interaction with DRIL1 protein bound to Ni-agarose
beads (lane 2). However, it showed a strong interaction
with both PKR (lane 3) and PACT (lane 4) bound to
Ni-agarose beads. These results further conﬁrm the in vivo
interaction detected between these proteins in yeast two-
hybrid assay.
hDus2 containsone copy ofevolutionarily conserved
dsRBM and interacts withdsRNA
Homology searches with Genbank sequences revealed that
hDUS2 contains two domains, the DUS domain that
functions in the enzymatic activity in modifying the
uridines in tRNAs post-transcriptionally (50). The DUS
domain in hDUS2 is located between residues 15 and 338
(Figure 1D). In addition to this, one copy of the
previously characterized evolutionarily conserved
dsRBM (30) is present in hDUS2 between residues 370
and 434. An alignment of the dsRBM of hDUS2 with the
dsRBMs present in PKR, PACT and TRBP is shown
in Figure 1E. The consensus residue lysine at position 58
of the dsRBM is absent in hDUS2 motif. This lysine has
previously been shown to be important for conferring a
high-aﬃnity binding to dsRNA (52,54). It is noteworthy
that hDUS2 has a glutamic acid at this position, thus
raising a possibility that the dsRBM present in hDUS2
Figure 1. Identiﬁcation of hDUS2 as PKR and PACT interacting
protein. (A) Yeast two-hybrid interaction assay. The indicated plasmids
were transformed into yeast strain Hf7C and the transformants were
streaked on triple dropout medium lacking leucine, tryptophan
and histidine. A: hDUS2/pGBKT7 and empty vector pGADT7, B:
hDUS2/pGBKT7 and PKR/pGADT7, C: hDUS2/pGBKT7 and
PACT/pGADT7, D: empty vector pGBKT7 and hDUS2/pGADT7,
E: PKR/pGBKT7 and hDUS2/pGADT7, F: PACT/pGBKT7 and
hDUS2/pGADT7. (B) b-Galactosidase assay for the interactions in
yeast. The indicated plasmids were transformed into yeast strain Hf7C
and the transformants were streaked on double dropout medium
lacking leucine, and tryptophan. After 4 days the growth was lifted on
nitrocellulose membrane and b-galactosidase activity assay was
performed after lysis of yeast cells on the membrane. Blue color
indicates a positive interaction and white color indicates no interaction.
(C) Biochemical interaction assay. In vitro-translated hDUS2 protein
was allowed to interact with hexahistidine-tagged pure recombinant
PKR or PACT proteins that were bound to Ni-agarose aﬃnity beads.
The bound proteins remaining on the beads were analyzed by SDS–
PAGE followed by phosphorimager analysis. Lane 1: total protein
from the translation mix (20% of input in lanes 2–4), lanes 2–4: hDUS2
protein bound to beads. Lane 2: protein bound to his-DRIL1 beads:
negative control, lane 3: protein bound to his-PKR beads, lane 4:
protein bound to his-PACT beads. (D) Domain structure of hDUS2.
A schematic representation of the DUS and dsRBM domains in
hDUS2 protein. The DUS domain is shown as a hatched box and the
dsRBM is shown as a gray box. The amino acid numbers are indicated
on the top and bottom of the boxes. (E) Alignment of hDUS2 dsRBM
with dsRBMs from three other human dsRNA-binding proteins PKR,
PACT and TRBP. ClustalW alignment of the dsRBMs present in PKR,
PACT and TRBP is shown. The conserved residues are shown in dark
gray and similarities are shown in light gray. The consensus is shown at
the bottom.
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examined this by comparing the binding of hDUS2,
PACT and PKR to dsRNA covalently linked to agarose
beads. As seen in Figure 2A, hDUS2 showed binding to
dsRNA at 50mM salt concentration but not at 300mM
salt. PACT and PKR both showed very strong binding to
dsRNA at 50 and 300mM salt concentrations. The
binding of hDUS2 to dsRNA at 50mM salt concentration
is quite signiﬁcant since ﬁreﬂy luciferase, a protein that is
known not to interact with dsRNA does not show binding
to dsRNA at this salt concentration. These results indicate
that although hDUS2 interacts with dsRNA, its aﬃnity
for dsRNA is much lower than PACT and PKR. This
could be due to the lack of the conserved lysine at position
58 of hDUS2 dsRBM, since this lysine is required for the
high-aﬃnity interaction with dsRNA (52,54).
hDus2 interactswith PACT and PKRin mammalian cells
In order to test if hDUS2 interacts with PACT and PKR
in mammalian cells, we tested the ability of ﬂag-tagged
hDUS2 to interact with HA-tagged PKR and PACT in
HeLa cells. As shown in Figure 2B, when ﬂag-hDUS2 was
immunoprecipitated with anti-ﬂag antibody, HA-tagged
PKR and PACT both co-immunoprecipitated with it
indicating that hDUS2 interacts with both PKR and
PACT. The negative control HA-B56a, which is an
unrelated protein, did not co-immunoprecipitate with
ﬂag-hDUS2, thus demonstrating the speciﬁcity of inter-
action. These results demonstrate that hDUS2 forms a
complex with PKR and PACT in mammalian cells.
Mapping the interaction domainsin PKR and hDus2
To map the domains within PKR that mediate its
interaction with hDUS2, we tested the interaction of
hDUS2 with two diﬀerent deletion mutants of PKR using
the in vitro interaction assay. In vitro translated
35S-methionine labeled PKR proteins were mixed with
pure, hexahistidine-tagged hDUS2 recombinant protein
and Ni-agarose beads and the proteins that bound to
hDUS2 were analyzed by SDS–PAGE. The DRBD
mutant lacks the carboxy-terminal residues 171–551 and
the 170 mutant lacks the amino-terminal residues 1–170
(12). As seen in Figure 3A, wild-type PKR showed
interaction with hDUS2 (lane 4) and DRBD showed a
very strong interaction with hDUS2 (lane 5). However,
170 did not show any interaction with hDUS2 (lane 6).
These results establish that PKR interacts with hDUS2 via
its DRBD. This region contains both the dsRBMs of
Figure 3. Mapping the hDUS2 interaction domain within PKR.
(A) PKR and its deletion mutants DRBD and 170 were in vitro
translated. Hexahistidine-tagged, pure recombinant hDUS2 protein was
incubated with 5ml of the reticulocyte lysates before pull-down with
Ni-charged aﬃnity resin. As a negative control, his-tagged DRIL1
protein that does not interact with PKR was immobilized on
Ni-agarose beads in lanes 7–9. The proteins that associate with
recombinant hDUS2 are also pulled down with the beads and were
analyzed by SDS–PAGE followed by phosphorimager analysis. Lanes
1–3 represent total proteins from the translation mix (20% of input in
lanes 4–9), lanes 4–6 represent proteins pulled down with hDUS2
bound to Ni-charged beads, and lanes 7–9 represent negative controls
with proteins pulled down with DRIL1 bound to Ni-charged beads.
(B) Mapping the PKR interaction domain within hDUS2. hDUS2 and
its deletion mutant 307 were in vitro translated. Hexahistidine-tagged,
pure recombinant PKR protein was incubated with 5ml of the
reticulocyte lysates before pull-down with Ni-charged aﬃnity resin.
As a negative control, his-tagged DRIL1 protein that does not interact
with hDUS2 was used in lanes 5 and 6. Lanes 1 and 2 represent total
proteins from the translation mix (20% of input in lanes 4–9), lanes 3
and 4 represent proteins pulled down with hexahistidine-tagged pure
recombinant PKR bound to Ni-charged beads, lanes 5 and 6 represent
negative controls with proteins pulled down with his-tagged pure
DRIL1 bound to Ni-charged beads.
Figure 2. hDUS2 interaction with dsRNA, PACT, and PKR.
(A) dsRNA-binding characteristics of hDUS2. Binding of hDUS2 to
dsRNA was analyzed by polyI:polyC-agarose-binding assay. The
binding was assayed at 50 and 300-mM salt concentration as indicated.
The T lanes represent total proteins from reticulocyte lysates. The
positions of hDUS2, PACT, PKR and Luciferase (Luc) are indicated
by arrows. (B) hDUS2 interaction with PACT and PKR in mammalian
cells. HeLa cells were transfected with (i) HA-B56a/pCDNA3.1
(–)+Flag-hDUS2/pCDNA3. (-1), (ii) HA-PACT/pCDNA3.1
(–)+Flag-hDUS2/pCDNA3.1(–) and (iii) HA-PKR/pCDNA3.1
(–)+Flag-hDUS2/pCDNA3.1(–). Twenty-four hours after transfection
the Flag-tagged hDUS2 protein was immunoprecipitated using
anti-Flag monoclonal antibody conjugated to agarose. The immuno-
precipitates were analyzed by western blot analysis with anti-HA
monoclonal antibody. The positions of HA-PKR, HA-PACT and Flag-
hDUS2 are as indicated by arrows.
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interactions. When an unrelated protein DRIL1 was
immobilized on the Ni-agarose beads, none of the
in vitro translated protein showed any interaction with
it, thereby demonstrating speciﬁcity of the interactions
between hDUS2 and PKR. In order to map the domain
within hDUS2 that mediates the interaction with PKR,
similar experiments were done with a deletion mutant of
hDUS2. 307 lacks the amino-terminal residues 1–307.
In vitro-translated
35S-methionine-labeled hDUS2 pro-
teins were mixed with pure, hexahistidine-tagged PKR
recombinant protein and Ni-agarose beads and the
proteins that bound to PKR were analyzed by SDS–
PAGE. As seen in Figure 3B, full-length hDUS2 and
307 both showed interaction with PKR (lanes 3 and 4).
The 307 mutant of hDUS2 lacks the amino-terminal
DUS domain but retains the single dsRBM present in
hDUS2, thus indicating that its interaction with PACT
and PKR is mediated via its dsRBM. The negative control
protein DRIL1 did not show any binding to hDUS2, thus
demonstrating that the interaction between PKR and
hDUS2 is speciﬁc.
To further test the contribution of the two dsRBMs
within DRBD of PKR in mediating interaction with
hDUS2, we tested the ability of several PKR point
mutants within the two motifs (52) to interact with pure
recombinant hDUS2 using the in vitro interaction assay.
The results are shown in Figure 4. As seen in the bar
graph, F41A, K60A and A68D mutants within dsRBM1
showed severely reduced interaction with hDUS2.
A mutation of the same residues in dsRBM2 was less
detrimental to the interaction with hDUS2. These results
strongly indicate that the interaction of PKR with hDUS2
is primarily mediated by its dsRBM1 of PKR and that the
residues F41, K60, and A68 serve an important function.
hDus2 inhibits PKR’s kinase activity bothin vitro and invivo
In order to understand the functional consequence of
hDUS2’s interaction with PKR, we tested the eﬀect of
hDUS2 on PKR’s kinase activity using the in vitro kinase
activity assay. As seen in Figure 5A, recombinant hDUS2
inhibited the PKR kinase activity in a dose-dependent
manner. hDUS2 was capable of inhibiting PKR activity
when it was activated by dsRNA as well as PACT. These
results demonstrate that hDUS2 acts as a PKR inhibitor.
To test this further in vivo in mammalian cells, we
performed the translation inhibition assay to check for
PKR activation. The eﬀect of a protein encoded by an
expression construct on activation of PKR in mammalian
cells can be measured by assaying the expression of a
co-transfected reporter gene such as luciferase (12). Using
the translation inhibition assay (46,55–58), we next
determined the ability of the hDUS2 expression constructs
to inhibit PKR in HeLa cells. As seen in Figure 5B,
co-transfection with wild-type PKR reduced luciferase
activity dramatically, whereas co-transfection with TRBP
expression construct increased the reporter activity, due to
inhibition of endogenous PKR activation. Co-transfection
with hDUS2 expression construct also increased luciferase
activity in a dose-dependent manner, indicating that
hDUS2 inhibits the activation of PKR. These results
further indicate that hDUS2 is not a very strong inhibitor
of PKR since it did not increase the reporter activity to the
same extent as the TRBP expression construct. At 100ng
DNA concentration, hDUS2 construct showed only about
half as much increase in activity of the reporter than the
TRBP construct. Thus, although hDUS2 does inhibit
PKR activity, it does not act as eﬃciently as TRBP. These
results indicate that to achieve an eﬀective inhibition of
PKR activity, hDUS2 may need to be expressed at high
levels relative to PKR levels in mammalian cells. In order
to test if hDUS2 overexpression can eﬀectively inhibit
activated PKR, we tested if co-transfected hDUS2
expression construct can relieve the translational repres-
sion of luciferase expression caused by active PKR. As
seen in Figure 5C, co-transfection of the reporter plasmid
with wild-type PKR expression construct reduced lucifer-
ase activity dramatically, whereas co-transfection with
hDUS2 expression construct along with wt PKR increased
the reporter activity in a dose-dependent manner.
Co-transfection of PKR expression construct with an
Figure 4. PKR’s interaction with hDUS2 is mediated by dsRBM1
motif within its DRBD. PKR and its point mutants were analyzed for
interaction with hexahistidine tagged pure, recombinant hDUS2 by
Ni-agarose pull-down assay. PKR and its point mutants were in vitro
translated. Hexahistidine-tagged, pure recombinant hDUS2 protein was
incubated with 5ml of the reticulocyte lysates before pull-down with
Ni-charged aﬃnity resin. As a negative control, his-tagged DRIL1
protein that does not interact with PKR was immobilized on
Ni-agarose beads. The proteins that associate with recombinant
hDUS2 are also pulled down with the beads and were analyzed by
SDS–PAGE followed by phosphorimager analysis. The percent
interaction was calculated using quantiﬁcation of radioactivity present
in the PKR band in the total and bound samples as follows: %
interaction=100 (amount of radioactivity in the bound sample/
amount of radioactivity in the total sample). The percent interactions
of the point mutants are expressed relative to that of the wild-type
PKR with wild-type PKR value taken as 100%. The amount of
radioactivity in the negative control (this was never above background
in any of the samples) was subtracted from the amount of radioactivity
in the bound sample before calculations. Error bars represent SE
calculated based on values from three diﬀerent experiments.
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no eﬀect on PKR activation showed no eﬀect on the
reporter gene activity thus demonstrating that the
inhibitory eﬀect of hDUS2 on PKR activation is speciﬁc.
These results strongly indicate that hDUS2 is able to
inhibit the PKR activity in mammalian cells.
Functional consequence of hDus2-mediated inhibition of
PKR activity
The inhibitory eﬀect of hDUS2 being weaker than TRBP
(Figure 5B), we tested the biological signiﬁcance of it.
Since PKR is known to be involved in stress signal-
induced apoptosis, we tested if overexpression of hDUS2
can inhibit apoptosis induced by tunicamycin, an anti-
biotic that causes endoplasmic reticulum (ER) stress due
to accumulation of unfolded proteins in the ER (59). PKR
is involved in inducing apoptosis in response to ER stress
(60,61). As seen in Figure 6, treatment of HT1080 cells
with tunicamycin induced cell death in about 38% of cells
transfected with the empty vector at 24h, which further
increased to about 52% at 48h. In cells transfected with
hDUS2 expression construct, tunicamycin induced cell
death in about 30% cells at 24h, which showed only an
extremely marginal increase to about 34% at 48h. The
transfected samples that were not treated with tunicamy-
cin did not show signiﬁcant cell death. Thus, at 48h after
treatment with tunicamycin, there is a signiﬁcant inhibi-
tion of cell death by overexpression of hDUS2 indicating
that hDUS2 is able to inhibit PKR activation and the
consequent apoptosis. These results establish that inhibi-
tion of PKR activity by hDUS2 may play an important
role in regulating stress-induced apoptosis.
DISCUSSION
PKR activity is regulated very tightly in cells and several
cellular proteins have been described as inhibitors of PKR
(47). One of the best-studied proteins is p58
IPK, which is a
member of the tetratricopeptide repeat family (62–64).
P58IPK inhibits PKR activity by interacting directly with
it and by preventing its dimerization (65). Inﬂuenza virus
evades the host antiviral response partially by recruiting
p58
IPK to repress PKR-induced eIF2a phosphorylation
(66). TRBP is a cellular protein that was identiﬁed by its
ability to bind human immunodeﬁciency virus type 1
(HIV-1) TAR RNA (67). TRBP inhibits PKR activity by
sequestration of its activator dsRNA, and also by direct
interaction with PKR (38,58). Recent data suggests that in
astrocytes, low TRBP levels support and innate HIV-1
Figure 5. hDUS2 inhibits PKR activity in vitro and in vivo.( A) PKR
kinase activity assay. PKR immunoprecipitated from HeLa cell extracts
was activated by the addition of 0.1mg/ml of poly(I): poly(C) (lanes
2–5) or 0.116pmol of recombinant PACT (lanes 6–9). The eﬀects of
addition of increasing amounts of recombinant hDUS2 protein were
assayed. Lane 1: no activator added, lanes 2 and 6: no hDUS2 added,
lanes 3 and 7: 1.45pmol (80ng) hDUS2, lanes 3 and 8: 7.25pmol
(400ng) hDUS2, lanes 4 and 9: 36.25pmol (2mg) hDUS2. The position
of phosphorylated PKR is indicated by an arrow. (B) Translation
inhibition assay. The translation inhibition assay was performed in
HeLa cells grown in six-well plates. The reporter pGL2C (200ng) was
co-transfected using Eﬀectene reagent with indicated amounts of the
empty vector control or expression constructs for TRBP, hDUS2 or
PKR. The amount of DNA in each well was kept constant at 600ng by
addition of required amounts of empty vector pCDNA3.1(–). At 24h
after transfection, the cells were treated with 100U/ml interferon-b
and 24h after the treatment the luciferase activity was measured in
the cell extracts and normalized to the total protein in the extract.
All expression constructs were in pCDNA3.1(–). (C) hDUS2 over-
expression relieves the translation inhibition caused by activated PKR.
The translation inhibition assay was performed in HeLa cells grown in
six-well plates. The reporter pGL2C (50ng) was co-transfected using
Eﬀectene reagent with indicated amounts of the empty vector
pCDNA3.1(–), expression constructs for PKR, hDUS2 and DRIL1.
The amount of DNA in each well was kept constant by addition of
required amounts of empty vector pCDNA3.1(–). At 24h after
transfection, the cells were treated with 100U/ml interferon-b.
Twenty-four hours after the treatment the luciferase activity was
measured in the cell extracts and normalized to the total protein in the
extract. All expression constructs were in pCDNA3.1(–).
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a major role in viral expression by regulating PKR
activation. NPM is an abundant nucleolar phosphopro-
tein implicated in ribosome biogenesis (69). NPM interacts
with PKR and inhibits eIF2a phosphorylation and PKR-
mediated apoptosis (70). NPM has also been implicated in
mediating antiviral activity of the tumor suppressor ARF
thus linking the Arf/mdm2/p53 pathway to PKR (71). The
heat shock proteins Hsp70 and Hsp90 have also been
shown to bind to PKR and inhibit its activation (48,72).
In addition to these cellular inhibitors of PKR, numerous
viral proteins and RNAs have been established to act as
PKR inhibitors during viral infection thereby evading the
host cell’s innate antiviral response (8,49).
In this article, we describe hDUS2 as a novel inhibitor
of PKR activity. hDUS2 was reported recently to have
39% homology to Dus2 enzyme of Saccharomyces
cerevisiae and to possess tRNA–DUS activity (50). It
was also shown to exist in a complex with EPRS, a
glutamy-prolyl tRNA synthetase and to enhance general
translational eﬃciency in mammalian cells. hDUS2 was
identiﬁed as a PACT-interacting protein in our yeast
two-hybrid screen using PACT as a bait. Further
characterization of the interaction between PACT and
hDUS2 (data not shown) indicated that this interaction
was mediated by the single copy of dsRBM present in
hDUS2. Our work on PKR and PACT has demonstrated
that PKR and PACT interact with each other via the
dsRBM motifs (45). The amino-terminal two copies of
dsRBM present in PACT are essential for mediating the
high-aﬃnity interaction with PKR via the two dsRBMs
present in PKR. We reasoned that hDUS2 may also show
interaction with PKR via the two dsRBMs. Originally
identiﬁed as a PACT-interacting protein, hDUS2 did
indeed interact with PKR equally well, both in vivo
(in mammalian and yeast cells) and in vitro. Although
there are two copies of dsRBM present in PKR, our
results indicate that hDUS2 interacts with PKR mainly
via the amino-terminal copy of the motif. Thus, the two
dsRBMs do not contribute equally to PKR’s interaction
with hDUS2 and the ﬁrst or the amino-terminal motif is
responsible for mediating the interaction. Within this
motif, mutations at position 41 (phenylalanine), 60 (lysine)
and 68 (alanine) aﬀected the interaction between PKR and
hDUS2 adversely, thereby identifying these residues as
essential for the interaction. Mutations of the same
residues in motif 2 did not show much eﬀect on the
PKR–hDUS2 interaction. In addition to this, the interac-
tion between hDUS2 and PKR is by direct protein–
protein interaction and not likely to be mediated via
dsRNA since mutations F131A, K150A, K154E and
A158D that are known to destroy PKR’s dsRNA binding
(26,52) have very little adverse eﬀect on PKR–hDUS2
interaction. Although hDUS2 carries one copy of the
conserved dsRBM, it does not interact with dsRNA with
high aﬃnity. This may be attributed to the lack of a
crucial conserved lysine at position 58 of the conserved
motif (Figure 1E). This lysine has been shown to be
essential for the high-aﬃnity interaction with dsRNA (52).
hDUS2 carries an aspartic acid residue at this position,
which may contribute to its lack of high-aﬃnity dsRNA
binding.
Recombinant hDUS2 protein showed a marked inhibi-
tion of PKR’s kinase activity in vitro. The inhibition was
eﬀective when PKR was activated either by addition of
dsRNA or recombinant PACT. However, hDUS2 was
eﬀective in inhibiting PACT-induced PKR activation
more eﬃciently than dsRNA-induced PKR activation
since even the lowest amount of hDUS2 (80ng) showed a
marked reduction in PKR autophosphorylation when
activated by PACT. This may be due to the ability of
hDUS2 to interact both with PKR and PACT. hDUS2’s
interaction with PACT may inhibit PACT’s interaction
with PKR in addition to inhibition by directly interacting
with PKR, thus resulting in a more eﬃcient inhibition.
The biological signiﬁcance of this if any is currently
unknown. hDUS2 also showed inhibition of PKR in
mammalian cells as seen in the translation inhibition
assay. However, hDUS2 did not inhibit PKR activation as
eﬃciently as PKR’s well-studied inhibitor TRBP
(Figure 5B). Since this is not due to lower level of
expression of hDUS2 as compared to TRBP (data not
shown), we conclude that hDUS2 is not a strong inhibitor
of PKR in vivo.
However, since the results shown in Figure 5C indicate
that when overexpressed, hDUS2 can inhibit activated
PKR it can be speculated that hDUS2 may regulate PKR
activity under conditions (or in cells) where its expression
Figure 6. hDUS2 overexpression inhibits stress-induced apoptosis.
HT1080 cells were grown to 50% conﬂuency on coverslips in six-well
plates and transfected with 500ng of pCDNA3.1(–)+100ng of
pEGFPC1 (white bars) or 500ng of hDUS2/pCDNA3.1(–)+100ng
of pEGFPC1 (black bars) using the Eﬀectene reagent. The cells were
observed for GFP ﬂuorescence 24h after transfection using an inverted
ﬂuorescence microscope. At this point, they were treated with 0.1mg/ml
of tunicamycin. The morphology of cells was monitored at regular time
intervals. At 24 and 48h after treatment, the cells were ﬁxed and
mounted in Vectashield with DAPI nuclear stain. At least 300
ﬂuorescent (GFP-positive) cells were counted as live or dead based
on their morphology and nuclear condensation indicated by intense
DAPI ﬂuorescence. The experiment was repeated three times and the
data is represented as averages of these values. The assays were counted
in blinded manner to ascertain the validity of observed diﬀerences. The
percentage of apoptotic cells were calculated using the formula, %
apoptosis=(ﬂuorescent dead cells with intense DAPI ﬂuorescence/total
ﬂuorescent cells) 100. The P-values, calculated using statistical
analysis, are as indicated above the bars.
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biological relevance under conditions where hDUS2
expression is upregulated in mammalian cells. In this
context, it has been recently reported that hDUS2 is
overexpressed in human nonsmall cell lung carcinomas
(NSCLC). It was observed that upregulation of hDUS2
was a relatively common feature of pulmonary carcino-
genesis and that selective suppression of hDUS2 by
SiRNA showed reduced growth rate in NSCLC cell lines
(50). Inhibition of PKR activity in NIH 3T3 cells by
expression of a trans-dominant negative PKR mutant has
been shown to lead to cell transformation and tumor
formation in nude mice (4,5). Overexpression of PKR
inhibitors p58
IPK and TRBP also results in tumorigenesis
(73). It remains to be tested if overexpression of hDUS2
also can lead to cell transformation. In addition, it would
also be interesting to examine if hDUS2-mediated inhibi-
tion of PKR is involved in tumorigenesis in cases of
NSCLC. Since our results demonstrate that hDUS2 can
inhibit apoptosis, overexpression of hDUS2 in NSCLC
may oﬀer a growth advantage to cancer cells.
hDUS2 has been shown to enhance the translation rate
in mammalian cells possibly by enhancing the tRNA
modiﬁcation activity of EPRS complex (50). In view of the
results presented here, it is also possible that hDUS2 may
enhance the rate of translation by inhibition of eIF2a
phosphorylation brought about by activated PKR. This
may be of biological signiﬁcance in cancer progression
since enhanced PKR expression is reported in some
types of cancers. In melanomas and colorectal cancers,
PKR overexpression can be correlated with enhanced
PKR activity (74). However, in breast cancer cells, PKR
overexpression does not correlate with increased PKR
activity (17,75). It is thought that an inhibitor of
PKR may be expressed at high levels in such cancers,
leading to an inhibition of PKR activity. In future, it
would be of interest to examine if hDUS2 may be involved
in PKR inhibition in these types of cancers.
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